Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.91 USD | +3.85% | -8.36% | -25.13% |
05-10 | UBS Cuts Price Target on Arrowhead Pharmaceuticals to $71 From $75, Keeps Buy Rating | MT |
05-09 | Arrowhead Pharmaceuticals Swings to Loss in Fiscal Q2 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.13% | 2.85B | |
+5.33% | 111B | |
+12.11% | 106B | |
-12.56% | 22.24B | |
-3.64% | 21.25B | |
-5.94% | 18.97B | |
-35.21% | 18.52B | |
-10.86% | 16.81B | |
+37.57% | 12.54B | |
-26.24% | 8.09B |
- Stock Market
- Equities
- ARWR Stock
- News Arrowhead Pharmaceuticals, Inc.
- RBC Capital Adjusts Price Target on Arrowhead Pharmaceuticals to $77 From $83 on Hepatitis B Virus Therapy Deprioritization, Keeps Outperform Rating